Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

465.07 +3.36 (+0.73%)
Streaming Delayed Price Updated: 3:26 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
54 55 Next >
2 Biotech Stocks That Could Help Make You a Fortune
Biotech stocks with cutting-edge therapies have the potential to generate substantial returns over time. 
Via The Motley Fool
3 No-Brainer Stocks to Buy in June
These biopharma stocks could be big winners. 
Via The Motley Fool
Breakthrough in CRISPR-Based Therapy: FDA Accepts Vertex and CRISPR Therapeutics' Exa-cel Application
The FDA has accepted the application for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG (NASDAQ: CRSP) exa-cel for sickle cell disease and transfusion-dependent  
Via Benzinga
Vertex/CRISPR Partnered Cell Therapy Shows Encouraging In Sickle Cell Disease, Thalassemia Patients
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent... 
Via Benzinga
Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
$1000 Invested In This Stock 15 Years Ago Would Be Worth $10,000 Today
Via Benzinga
CRISPR Therapeutics: A Galaxy's Worth of Deep Value
Wall Street is at max pessimism with this biotech, which might be a big mistake. 
Via The Motley Fool
Why Is CRISPR Therapeutics (CRSP) Stock Moving Today?
CRISPR Therapeutics (CRSP) stock is on the move Friday after the company revealed data from its CLIMB-111 and CLIMB-121 clinical trials. 
Via InvestorPlace
Crispr Stock Slips; The FDA Could Approve The First CRISPR-Based Gene-Editing Drug In Just Six Months
The agency said it will make an approval decision on Crispr's exa-cel in December. 
Via Investor's Business Daily
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Expert Ratings for Vertex Pharmaceuticals
Via Benzinga
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
From Vertex Pharmaceuticals Incorporated
Via Business Wire
5 Top Stocks to Buy in June
There are always buying opportunities in the stock market. 
Via The Motley Fool
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
Today, CRISPR has reached an important turning point. 
Via The Motley Fool
A New S&P 500 Bull Market Is Nearly Here: 3 No-Brainer Stocks to Buy Sooner Rather Than Later
These stocks are already performing well but could kick into higher gear in a new S&P 500 bull market. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for June
These stocks have what it takes to deliver long-term growth. 
Via The Motley Fool
Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?
This company might be worth a premium. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $250,000 in These 3 Stocks and Wait a Decade
All three trounced the market over the past 10 years. 
Via The Motley Fool
Got $1,000? 2 Amazing Growth Stocks That Could Help You Retire Richer
These businesses have considerable growth runways ahead. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For May 30, 2023
Via Benzinga
Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Wall Street Thinks This Stock Will Only Rise 12%: Here's Why It Could Jump a Lot More
Analysts could be too reserved about this biotech stock's prospects. 
Via The Motley Fool
Want to Get Richer? 3 Top Stocks to Buy Now and Hold Forever
These stocks have what it takes to help you build long-term wealth. 
Via The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
These stocks should be winners in good times and bad times. 
Via The Motley Fool
2 Supercharged Stocks to Buy With $100
These stocks are climbing in the double digits. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Biotech Stocks That Could Help Set You Up for Life
These two promising companies have the potential to beat the market over time. 
Via The Motley Fool
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Thursday, Gilead Sciences stock had its Relative Strength (RS) Rating upgraded to 81, up from 78 a day earlier. 
Via Investor's Business Daily
2 Top Trends to Invest $5,000 in Right Now
Renewable energy and gene-editing medical therapies are poised to grow exponentially. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.